Anúncio
Anúncio

SLRX

SLRX logo

Salarius Pharmaceuticals, Inc. Common Stock

0.83
USD
Patrocinado
-0.01
-0.60%
08 de jan., 09:30 UTC -5
Encerrado
exchange

Pós-Mercado

0.83

0.00
0.00%

Relatórios de Lucros SLRX

Rácio de surpresa positiva

SLRX separação 18 de 28 últimas estimativas.

64%

Próximo Relatório

Data do Próximo Relatório
19 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$6.00
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
--

Salarius Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 14 de nov. de 2025, SLRX reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -6.00 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -23.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -6.00 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Salarius Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
The stock price moved down -23.41%, changed from $1.20 before the earnings release to $0.92 the day after.
The next earning report is scheduled for 19 de mar. de 2026.
Based on 3 analistas, Salarius Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$6.00 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio